Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AB Science S.A.

http://www.ab-science.com/

Latest From AB Science S.A.

China’s Lead mRNA COVID-19 Vaccine Candidate Faces Phase III Delays

The leader in China's homegrown mRNA COVID-19 vaccine effort expects a delay to key Phase III results, with analysts now expecting to see figures from the international portion of the study in early 2022.

China Coronavirus COVID-19

Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

China Deals

Junshi Joins China mRNA Mania Through Immorna JV

After immuno-oncology, mRNA is fast becoming a hot area in China as a flurry of biotechs from I-Mab to Kangtai partner with a little-known developer.

Deals China

Newest Biotech Joins China mRNA COVID Vaccine Race

Additional Chinese coronavirus vaccine makers are now building up capacity, with Beijing-based AIM Vaccine preparing for a 400 million dose per year production capability for mRNA vaccines, while Chengdu-based Clover is to supply up to 414 million doses of its vaccines to GAVI.

China Coronavirus COVID-19
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register